Could a common asthma drug help treat a rare genetic disorder?
NCT ID NCT04240821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether theophylline, a drug used for asthma, can help children and young adults with pseudohypoparathyroidism—a rare genetic condition causing early obesity, hormone problems, and short stature. Researchers will check for weight loss, better blood sugar control, and fewer hormone issues. About 34 people who completed a prior trial will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALBRIGHT HEREDITARY OSTEODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Long-Term study sheds light on rare bone and hormone disorder
- Why are people with this rare bone disorder prone to diabetes?
- Single-Patient trial aims to tackle obesity in rare bone disorder
- 2000-Patient study aims to uncover hidden metabolic risks in rare genetic disorders
- Old asthma drug shows promise for rare genetic disorder